SCHEMBL4675083

SCHEMBL4675083

O=C(C=C(O)c1nc[nH]n1)c1cocc1Sc1cccc(C(F)(F)F)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
SIRT2 Q8IXJ6 1/20 0.34
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NOTUM Q6P988 1/20 0.33
ALDH1A1 P00352 4/20 0.33
GAA P10253 2/20 0.33
XDH P47989 1/20 0.33
KDR P35968 1/20 0.33
POLB P06746 1/20 0.33
BRAF P15056 1/20 0.33
KDM4E B2RXH2 3/20 0.32
GPR52 Q9Y2T5 2/20 0.32
GRK6 P43250 1/20 0.32
MEN1 O00255 1/20 0.31
GMNN O75496 1/20 0.31
LMNA P02545 1/20 0.31
TTR P02766 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4673393 0.89 PPARD (0.32) ALDH1A1KDM4ESMN1; SMN2
SCHEMBL4675243 0.86 MEN1 (0.35) SLC6A2SLC6A4SLC6A3NOTUMGAA
SCHEMBL4675136 0.84 MEN1 (0.37) SIRT2L3MBTL1NOTUMALDH1A1KDM4E
SCHEMBL4671930 0.83 KDR (0.35) SLC6A2SLC6A4SLC6A3SIRT2ATM
SCHEMBL4670987 0.83 GPR52 (0.34) SIRT2ATML3MBTL1NOTUMALDH1A1
SCHEMBL4671054 0.83 KDM4E (0.34) NOTUMKDM4ELMNA
SCHEMBL4672042 0.82 SIRT2 (0.35) SIRT2ATML3MBTL1NOTUMALDH1A1
SCHEMBL4674659 0.81 ALDH1A1 (0.35) SIRT2ATML3MBTL1NOTUMALDH1A1
SCHEMBL4671076 0.80 ALDH1A1 (0.36) SIRT2ATML3MBTL1NOTUMALDH1A1
SCHEMBL4676929 0.80 KDM4E (0.38) L3MBTL1ALDH1A1GAAPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SLC6A2 513/4885SLC6A4 344/4885SLC6A3 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.